SOPH · SOPHiA GENETICS SA · Webcasts, Transcripts & Audio
$6.68
-0.79 (-10.58%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$572.20M
Shares
85.66M
Volume · Nov 19
1.58M
Avg daily vol (3M)
672.43K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
SOPHiA GENETICS SA Webcasts
Earnings calls, investor updates, investor days and conferences for SOPHiA GENETICS SA (SOPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-11
SOPHiA GENETICS SA (SOPH) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-03
SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript
Confident tone
Biopharma collaborations
Genomics application growth
Liquid biopsy adoption
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-04
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
Confident tone
AstraZeneca CDX Deals
Customer Implementations and Backlog
Capital Raise and Balance Sheet
Revenue
$23.31M
▲ 27.2% YoY Diluted EPS
$-0.30
Gross margin
64.6%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
SOPHiA GENETICS SA (SOPH) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
Confident tone
MSK Access and Biopharma
Path to Profitability and Efficiency
Revenue Growth and Platform Adoption
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
Confident tone
Customer wins and U.S. growth
Guidance and 2026 outlook
Platform modernization and scalability
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
Confident tone
MSK-ACCESS liquid biopsy franchise
Companion diagnostic (CDx) partnerships
New customer signings and expansion
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript
Confident tone
MSK-ACCESS liquid biopsy application
Revenue growth and BioPharma headwinds
AstraZeneca partnership
Revenue
$18.32M
▲ 15.9% YoY Diluted EPS
$-0.33
Gross margin
67.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
Confident tone
MSK-ACCESS and MSK-IMPACT applications
Biopharma partnerships
Platform scalability and AI
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
Confident tone
2025 Growth Drivers
New Application Launches (MSK)
2025 Financial Guidance
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
Positive tone
Leadership changes
Cost discipline and cash burn
MSK-ACCESS powered with SOPHiA DDM
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q2 2024 Earnings Call Transcript
Positive tone
BioPharma headwinds and restructuring
Platform and product launches
New customer signings and bookings
Revenue
$15.81M
▲ 5% YoY Diluted EPS
$-0.23
Gross margin
68.2%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q1 2024 Earnings Call Transcript
Positive tone
Backlog, bookings, and new logos
Biopharma business and deal delays
Applications: solid tumor, HRD, liquid biopsy, MSK Access
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q2 2023 Earnings Call Transcript
Revenue
$15.05M
▲ 29% YoY Diluted EPS
$-0.33
Gross margin
66.7%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q2 2022 Earnings Call Transcript
Revenue
$11.67M
Diluted EPS
$-0.39
Gross margin
65.3%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
SOPHiA GENETICS SA (SOPH) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–23 of 23 webcasts
Key facts
CIK
1840706
CUSIP
H82027105
13F (30d)
91 filings
89 filers
Visit website
Investor relations